Samsung Biologics Co. Ltd.

06/11/2025 | Press release | Distributed by Public on 06/11/2025 19:39

Utilizing small scale downstream studies across biologics manufacturing

Resource Library

Whitepapers

Utilizing small scale downstream studies across biologics manufacturing

  • Registered June 12, 2025
    • LINKEDIN
    • FACEBOOK

As biologic therapeutics become more complex and regulatory expectations continue to evolve, the importance of deep process understanding is increasingly recognized.


This whitepaper explores how small-scale downstream studies can support activities across the product lifecycle. From tech transfer and process validation to regulatory filings, these studies offer a practical, data-driven approach to assessing risk and confirming process robustness.


Learn how these tools are being applied to advance biologics manufacturing with reliability and flexibility.

As biologic therapeutics become more complex and regulatory expectations continue to evolve, the importance of deep process understanding is increasingly recognized.


This whitepaper explores how small-scale downstream studies can support activities across the product lifecycle. From tech transfer and process validation to regulatory filings, these studies offer a practical, data-driven approach to assessing risk and confirming process robustness.


Learn how these tools are being applied to advance biologics manufacturing with reliability and flexibility.

Attached
  • Utilizing small scale downstream studies across biologics manufacturing
Go List
Samsung Biologics Co. Ltd. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 12, 2025 at 01:40 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io